Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 112366
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112366
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112366
Involvement of bile acids in cholangiocarcinoma progression via the Hippo-yes-associated protein signaling pathway
Jun Hu, Gan Zhang, Xian-Feng Shen, Meng Zhou, Lin-Sheng Huang, Hao-Ming Lan, Department of Hepatopancreatobiliary Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China
Shuo Yang, Department of Ultrasound Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China
Co-first authors: Jun Hu and Gan Zhang.
Author contributions: Hu J, Zhang G, and Lan HM conducted the study, conceived and designed the study, edited and reviewed the manuscript draft; Yang S and Shen XF contributed to data acquisition and interpret the data; Zhou M and Huang LS analyzed the data; Hu J and Zhang G contributed equally to this manuscript and are co-first authors. All authors have read and approved the final manuscript.
Institutional animal care and use committee statement: All animal experiments were approved by the Ethics Review Committee of Taihe Hospital, Hubei University of Medicine (Approval No. SY-KY20250105).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Datasets used in this article are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao-Ming Lan, Department of Hepatopancreatobiliary Surgery, Taihe Hospital, Hubei University of Medicine, No. 32 Renmin South Road, Maojian District, Shiyan 442000, Hubei Province, China. bagwell1986@163.com
Received: July 25, 2025
Revised: August 29, 2025
Accepted: October 29, 2025
Published online: December 15, 2025
Processing time: 139 Days and 23.2 Hours
Revised: August 29, 2025
Accepted: October 29, 2025
Published online: December 15, 2025
Processing time: 139 Days and 23.2 Hours
Core Tip
Core Tip: Cholangiocarcinoma is a highly aggressive malignancy with limited therapeutic options. This study demonstrates that glycochenodeoxycholic acid promotes tumor growth and aggressiveness by activating the Hippo-yes-associated protein (YAP) signaling pathway, whereas deoxycholic acid suppresses tumor progression by enhancing YAP phosphorylation and inducing apoptosis. The use of YAP modulators further confirmed the opposing roles of these bile acids. These findings provide novel mechanistic insights and highlight YAP as a potential therapeutic target, offering new perspectives for bile acid-based intervention strategies in cholangiocarcinoma.